|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EXOSC10 |
Gene summary for EXOSC10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EXOSC10 | Gene ID | 5394 |
| Gene name | exosome component 10 | |
| Gene Alias | PM-Scl | |
| Cytomap | 1p36.22 | |
| Gene Type | protein-coding | GO ID | GO:0000184 | UniProtAcc | Q01780 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5394 | EXOSC10 | LZE4T | Human | Esophagus | ESCC | 2.69e-17 | 5.28e-01 | 0.0811 |
| 5394 | EXOSC10 | LZE7T | Human | Esophagus | ESCC | 1.04e-07 | 3.60e-01 | 0.0667 |
| 5394 | EXOSC10 | LZE8T | Human | Esophagus | ESCC | 6.92e-04 | 1.10e-01 | 0.067 |
| 5394 | EXOSC10 | LZE20T | Human | Esophagus | ESCC | 2.42e-04 | 2.00e-01 | 0.0662 |
| 5394 | EXOSC10 | LZE22T | Human | Esophagus | ESCC | 4.86e-05 | 4.13e-01 | 0.068 |
| 5394 | EXOSC10 | LZE24T | Human | Esophagus | ESCC | 1.95e-06 | 3.07e-01 | 0.0596 |
| 5394 | EXOSC10 | LZE21T | Human | Esophagus | ESCC | 4.20e-02 | 1.52e-01 | 0.0655 |
| 5394 | EXOSC10 | P1T-E | Human | Esophagus | ESCC | 1.67e-04 | 4.54e-01 | 0.0875 |
| 5394 | EXOSC10 | P2T-E | Human | Esophagus | ESCC | 1.08e-30 | 5.74e-01 | 0.1177 |
| 5394 | EXOSC10 | P4T-E | Human | Esophagus | ESCC | 4.33e-13 | 2.26e-01 | 0.1323 |
| 5394 | EXOSC10 | P5T-E | Human | Esophagus | ESCC | 3.11e-15 | 3.31e-01 | 0.1327 |
| 5394 | EXOSC10 | P8T-E | Human | Esophagus | ESCC | 1.39e-16 | 3.30e-01 | 0.0889 |
| 5394 | EXOSC10 | P9T-E | Human | Esophagus | ESCC | 1.55e-05 | 1.51e-01 | 0.1131 |
| 5394 | EXOSC10 | P10T-E | Human | Esophagus | ESCC | 1.81e-22 | 3.90e-01 | 0.116 |
| 5394 | EXOSC10 | P11T-E | Human | Esophagus | ESCC | 6.63e-15 | 5.39e-01 | 0.1426 |
| 5394 | EXOSC10 | P12T-E | Human | Esophagus | ESCC | 3.07e-13 | 3.25e-01 | 0.1122 |
| 5394 | EXOSC10 | P15T-E | Human | Esophagus | ESCC | 1.84e-16 | 4.60e-01 | 0.1149 |
| 5394 | EXOSC10 | P16T-E | Human | Esophagus | ESCC | 1.01e-17 | 3.45e-01 | 0.1153 |
| 5394 | EXOSC10 | P17T-E | Human | Esophagus | ESCC | 3.70e-18 | 5.90e-01 | 0.1278 |
| 5394 | EXOSC10 | P19T-E | Human | Esophagus | ESCC | 4.26e-03 | 6.66e-01 | 0.1662 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
| GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:0006403110 | Esophagus | ESCC | RNA localization | 166/8552 | 201/18723 | 1.95e-27 | 6.18e-25 | 166 |
| GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
| GO:003304416 | Esophagus | ESCC | regulation of chromosome organization | 145/8552 | 187/18723 | 3.80e-19 | 4.31e-17 | 145 |
| GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
| GO:0006402110 | Esophagus | ESCC | mRNA catabolic process | 170/8552 | 232/18723 | 8.70e-18 | 8.00e-16 | 170 |
| GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
| GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
| GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
| GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
| GO:005105215 | Esophagus | ESCC | regulation of DNA metabolic process | 232/8552 | 359/18723 | 2.40e-13 | 1.13e-11 | 232 |
| GO:000095618 | Esophagus | ESCC | nuclear-transcribed mRNA catabolic process | 88/8552 | 112/18723 | 9.41e-13 | 4.14e-11 | 88 |
| GO:000072319 | Esophagus | ESCC | telomere maintenance | 99/8552 | 131/18723 | 2.68e-12 | 1.08e-10 | 99 |
| GO:007189716 | Esophagus | ESCC | DNA biosynthetic process | 127/8552 | 180/18723 | 1.04e-11 | 3.85e-10 | 127 |
| GO:00905013 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301824 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa0301834 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa03018 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
| hsa030181 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
| hsa030182 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa030183 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa030189 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
| hsa0301814 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
| hsa0301823 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
| hsa0301833 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
| hsa0301822 | Prostate | Tumor | RNA degradation | 30/1791 | 79/8465 | 4.48e-04 | 2.35e-03 | 1.46e-03 | 30 |
| hsa0301832 | Prostate | Tumor | RNA degradation | 30/1791 | 79/8465 | 4.48e-04 | 2.35e-03 | 1.46e-03 | 30 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EXOSC10 | SNV | Missense_Mutation | c.1089N>C | p.Lys363Asn | p.K363N | Q01780 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0B3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| EXOSC10 | SNV | Missense_Mutation | c.1807G>C | p.Glu603Gln | p.E603Q | Q01780 | protein_coding | tolerated(0.14) | benign(0.058) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| EXOSC10 | insertion | Frame_Shift_Ins | novel | c.883_884insTTGAAATA | p.Asp295ValfsTer14 | p.D295Vfs*14 | Q01780 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| EXOSC10 | insertion | Nonsense_Mutation | novel | c.979_980insAGTGCTATAAATTTCCCTCTAC | p.Cys327Ter | p.C327* | Q01780 | protein_coding | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | ||
| EXOSC10 | SNV | Missense_Mutation | c.2654N>C | p.Arg885Thr | p.R885T | Q01780 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-EA-A43B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| EXOSC10 | SNV | Missense_Mutation | c.1465N>C | p.Glu489Gln | p.E489Q | Q01780 | protein_coding | tolerated(0.07) | benign(0.066) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| EXOSC10 | SNV | Missense_Mutation | novel | c.1162N>C | p.Asp388His | p.D388H | Q01780 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| EXOSC10 | SNV | Missense_Mutation | rs757576637 | c.1373N>A | p.Arg458His | p.R458H | Q01780 | protein_coding | tolerated(0.1) | possibly_damaging(0.608) | TCGA-ZJ-AB0I-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| EXOSC10 | SNV | Missense_Mutation | c.892N>A | p.Val298Met | p.V298M | Q01780 | protein_coding | tolerated(0.11) | benign(0.34) | TCGA-A6-2677-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Ancillary | leucovorin | SD | |
| EXOSC10 | SNV | Missense_Mutation | c.1904C>A | p.Ala635Glu | p.A635E | Q01780 | protein_coding | tolerated(0.23) | benign(0.003) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |